ALK Inhibitor Response in Melanomas Expressing EML4-ALK Fusions and Alternate ALK Isoforms

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Anaplastic lymphoma kinase (ALK) fusions are known oncogenic drivers in various cancers, susceptible to targeted ALK inhibitor therapies.
• The presence and therapeutic implications of ALK alterations in malignant melanoma remain largely uncharacterized.
• A novel ALK isoform (ALK) has been recently identified in a subset of melanomas, necessitating further investigation into its clinical relevance.

Observation:

• This study analyzed 45 melanoma patient-derived xenograft models for ALK expression, identifying ALK alterations in 24.4% of cases.
• Ten melanomas exhibited wild-type (wt) ALK and/or ALK expression, while one mucosal melanoma displayed novel EML4-ALK fusion variants.
• Melanoma cells with EML4-ALK fusions demonstrated sensitivity to ALK inhibitors in vitro and in vivo.

Findings:

• Melanomas harboring EML4-ALK fusions are sensitive to ALK inhibitors, indicating a potential targeted therapy approach.
• Conversely, melanomas expressing wt ALK or ALK isoforms did not respond to ALK inhibitor treatment.
• A patient with ALK-expressing mucosal melanoma showed no response to a broad-spectrum ALK/ROS1/TRK inhibitor.

Implications:

• Targeting ALK fusions represents a viable therapeutic strategy for a specific subset of melanoma patients.
• The efficacy of ALK inhibitors in melanomas with wt ALK or ALK isoforms requires further clinical investigation.
• These findings highlight the importance of molecular profiling for identifying actionable ALK alterations in melanoma treatment decisions.